Pharmacytimes: Resources: Rheumatoid Arthritis Rheumatoid Arthritis en-us Mon, 22 Jul 2019 01:56:08 UTC Mon, 22 Jul 2019 01:56:08 UTC Patients with Rheumatoid Arthritis Achieve Low Disease Activity with Tofacitinib Tofacitinib shows promising results in adult patients with moderately to severely active rheumatoid arthritis as a monotherapy with or without methotrexate. Study: Statins Prevent Cardiovascular Events for Rheumatoid Arthritis Research investigates whether statins are safe and effective for patients with inflammatory conditions, such as rheumatoid arthritis. FDA: Elevated Risk of Blood Clots in Lungs, Death in RA Patients on Higher Dose Tofacitinib A 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR, Pfizer) used in patients with rheumatoid arthritis increased the risk of blood clots in the lungs and death in a safety clinical trial. Upadacitinib Granted Priority Review for Moderate-to-Severe Rheumatoid Arthritis The New Drug Application for upadacitinib is supported by data from the phase 3 SELECT trial program evaluating patients with moderate-to-severe rheumatoid arthritis. Rheumatoid Arthritis Biosimilar Meets Equivalency Endpoints in Phase 1/3 Trial Rituximab is approved by the FDA for the treatment of adults with rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, pemphigus vulgaris, granulomatosis with polyangiitis and microscopic polyangiitis. FDA Approves New Autoinjector Formulation of Actemra The single-dose, prefilled autoinjector for tocilizumab (Actemra) offers an additional option for patients with rheumatoid arthritis, giant cell arteritis, and 2 forms of juvenile arthritis. Rheumatoid Arthritis Treatment Regimens Not Being Changed to Hit Low-Disease Activity Target New data presented at the 2018 ACR/ARHP Annual Meeting shows that the treatment regimens for many patients are not being changed to reach a “treat-to-target” goal for low disease activity. Pharmacy Week in Review: Narcolepsy Drug Approved for Children, Thyroid Disease Linked to RA Onset A look at last week's top stories in the world of pharmacy. FDA OKs Sandoz's Biosimilar Adalimumab-adaz Adalimumab-adaz (Hyrimoz), a biosimilar of Humira, is the third FDA-approved Sandoz biosimilar in the United States. Autoimmune Thyroid Disease Risk Associated with Onset of Rheumatoid Arthritis Study evaluates when and how the increased risk of autoimmune thyroid disease develops in patients diagnosed with rheumatoid arthritis. Tapering Biologic RA Treatment Successful, Cost-Effective in Certain Patients Patients with rheumatoid arthritis who achieve low disease activity or remission may successfully taper their biologic disease-modifying antirheumatic drugs, saving costs as a result. Analysis: Medicare Reform May Increase Access Barriers, Costs for Rheumatoid Arthritis Drugs Shifting Medicare Part B drugs into Part D may lead to higher costs for Medicare patients with rheumatoid arthritis, according to a new analysis. Link Between Rheumatoid Arthritis and Huntington Disease Discovered By mapping out the epigenomic landscape of rheumatoid arthritis, scientists hope to gain insight on disease origins as well as new cell signaling pathways. ACR Report Underscores Need for Improved Rheumatic Disease Care New report assesses the quality of rheumatic disease care across all 50 states and calls for improvements that address access to affordable care. Novel Rheumatoid Arthritis Drug Tops SPT Week in Review Top news of the week from Specialty Pharmacy Times. Novel Rheumatoid Arthritis Therapy Effective in Phase 3 Study New drug could serve as a potential treatment option for patients who have shown an inadequate response to conventional disease-modifying drugs. Poor Prognosis Associated with Disease Progression in Rheumatoid Arthritis The rate of disease progression in patients with rheumatoid arthritis (RA) can be associated with a poor prognosis in patients. Childhood Secondhand Smoke Exposure Linked to Future Rheumatoid Arthritis Risk Exposure to secondhand smoke in childhood can lead to greater risk of rheumatoid arthritis later in life, even in non-smoking adults. Novel Therapies in Rheumatoid Arthritis A symposium presented at the Asembia Specialty Pharmacy Summit 2018 provided pharmacists a review of guideline-based RA management strategies, along with recent trial data on new and emerging agents. American College of Rheumatology Urges Policy Reform to Protect Patients with Rheumatology Diseases In response to the Trump Administration’s drug pricing blueprint, the American College of Rheumatology issued a set of policy principles on drug prices and access to rheumatology treatment. VSEO N/A